Comparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goats

• Published in: BMC veterinary research 2015-05, Vol.11 (1), p.124, Article 124
• Main Authors: Aksit, Dilek, Yalinkilinc, Hande Sultan, Sekkin, Selim, Boyacioğlu, Murat, Cirak, Veli Yilgor, Ayaz, Erol, Gokbulut, Cengiz
• Format: Article
• Language: English
• Subjects: Administration, Intravenous; Albendazole - administration & dosage; Albendazole - analogs & derivatives; Albendazole - blood; Albendazole - pharmacokinetics; Animals; Anthelmintics - administration & dosage; Anthelmintics - blood; Anthelmintics - pharmacokinetics; Area Under Curve; Comparative analysis; Dose-Response Relationship, Drug; Enantiomers; Female; Goats - blood; Goats - metabolism; Half-Life; High performance liquid chromatography; Injections, Subcutaneous; Male; Physiological aspects; Sheep - blood; Sheep - metabolism; Species Specificity
• ISSN: 1746-6148; 1746-6148
• DOI: 10.1186/s12917-015-0442-5

The aims of this study were to compare the pharmacokinetics of albendazole sulfoxide (ABZ-SO, ricobendazole) in goats and sheep at a dose of 5 g/kg bodyweight (BW), after intravenous (IV) and subcutaneous (SC) administrations, and to investigate the effects of increased doses (10 and 15 mg/kg BW) on the plasma disposition of ABZ-SO in goats following SC administration. A total of 16 goats (Capra aegagrus hircus, eight males and eight females) and 8 sheep (Ovis aries, four males and four females) 12-16 months old and weighing 20-32 kg, were used. The study was designed according to two-phase crossover study protocol. In Phase-1, eight sheep were assigned as Group I and 16 goats were allocated into two groups (Group II and Group III). ABZ-SO was applied to Group I (sheep) and Group II (goats) animals subcutaneously, and to Group III (goats) animals intravenously, all at a dose rate of 5 mg/kg BW. In Phase-2, the sheep in the Group I received ABZ-SO intravenously in a dose of 5 mg/kg BW; the goats in Group II and Group III received ABZ-SO subcutaneously at a dose of 10 mg/kg and 15 mg/kg BW, respectively. Blood samples were collected from the jugular vein at different times between 1 and 120 h after drug administrations. The plasma concentrations of ABZ-SO and its metabolites were analysed by high performance liquid chromatography. In goats, the area under the curve, terminal half-life and plasma persistence of ABZ-SO were significantly smaller and shorter, respectively, compared with those observed in sheep following both IV and SC administrations at a dose of 5 mg/kg BW. On the other side, dose-dependent plasma dispositions of ABZ-SO were observed following SC administration at increased doses (10 and 15 mg/kg) in goats. Consequently, ABZ-SO might be used at higher doses to provide higher plasma concentration and thus to achieve greater efficacy against the target parasites.